EE353 Cost-Consequence Analysis of Fremanezumab Treatment in Patients With Migraine and Comorbid Major Depressive Disorder in the UK Using Results From the UNITE Study
Abstract
Authors
D Mitsikostas AE Guevara Morel V. Ramirez-Campos MT Driessen R Jain